Alpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026
Alpha Tau Medical presented pooled results from two first-in-human trials of its Alpha DaRT therapy in pancreatic cancer, showing a 100% local disease control rate across 19 evaluable patients. The safety profile was favorable, with device-associated adverse events occurring in only 27% of treated subjects, nearly all of which resolved within two weeks.
Key figures
- Drug Name
- Alpha DaRT
- Phase Of Trial
- first-in-human
- Subjects treated
- 26
- Evaluable patients
- 19
- Stable disease rate
- 79%
- Partial response rate
- 21%
- Adverse events incidence
- 27%
- Local disease control rate
- 100%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.